Patients in the placebo arm of REDUCE-IT, who received mineral oil, saw worsening levels of numerous biomarkers linked to atherosclerotic disease during the trial, while those in the icosapent ethyl (Vascepa; Amarin) arm saw “minimal changes,” a new analysis shows. With the pharmaceutical-grade mineral oil, there were increases in interleukin-1β (IL-1β), lipoprotein-associated phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), lipoprotein(a), and homocysteine. Also increas...